TCON TRACON Pharmaceuticals, Inc.

5.60
+0.5  (9.8%)
Previous Close 5.10
Open 5.08
Price To book 3.74
Market Cap 73.16M
Shares 13,065,000
Volume 65,305
Short Ratio 1.43
Av. Daily Volume 58,114

SEC filingsSee all SEC filings

  1. 8-K - Current report 17515665
  2. 8-K - Current report 17502174
  3. 8-K - Current report 162062499
  4. 8-K - Current report 162049641
  5. SC 13D/A [Amend] - General statement of acquisition of beneficial ownership 162040723

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 dosing initiated May 2016 with data due early 2018.
TRC105 and Nexavar
Hepatocellular carcinoma (HCC) - cancer
Phase 2 initiated Dec 2014. Phase 2 data top-line PFS data due 2H 2017.
TRC105 and Inlyta
Renal Cell Carcinoma (RCC) - cancer
Phase 2 data due 1H 2017.
TRC105 and Avastin
Glioblastoma - cancer
Phase 2 planned for 2016. Data due 4Q 2017.
TRC105
Gestational Trophoblastic Neoplasia cancer
Phase 2 trial initiated January 2016.
TRC102 and Temodar
Glioblastoma - cancer
Phase 2 initiated October 2015. Data are due in 2017.
TRC102
Mesothelioma cancer
Phase 3 interim analysis due 1H 2018.
TRC105 and Votrient (pazopanib)
Angiosarcoma cancer
Phase 2 data due late 2016 according to 10Q filed November 2016. As of January 9, 2016, data have not been released and no mention of the trial was made in its January 9 presentation.
TRC105
Soft tissue sarcomas

Latest News

  1. TRACON PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclos
  2. TRACON PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
  3. Tuesday’s Biggest Biotech and Pharma Moves
  4. TRACON Pharmaceuticals Receives Special Protocol Assessment (SPA) Agreement from FDA for Phase 3 Clinical Trial of TRC105 in Angiosarcoma
  5. TRACON Pharmaceuticals Receives Special Protocol Assessment (SPA) Agreement from FDA for Phase 3 Clinical Trial of TRC105 in Angiosarcoma
  6. ETFs with exposure to TRACON Pharmaceuticals, Inc. : December 22, 2016
  7. Coverage initiated on Tracon Pharmaceuticals by Jefferies
  8. TRACON PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and
  9. TRACON PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and
  10. ETFs with exposure to TRACON Pharmaceuticals, Inc. : December 9, 2016
  11. TRACON Pharmaceuticals Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares
  12. TRACON PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
  13. TRACON Pharmaceuticals Announces Pricing of Public Offering of Common Stock
  14. TRACON Pharmaceuticals Announces Pricing of Public Offering of Common Stock
  15. TRACON Pharmaceuticals to Host Key Opinion Leader Luncheon for Investors Focused on Angiosarcoma and Prostate Cancer on December 1 in New York City
  16. TRACON Pharmaceuticals to Host Key Opinion Leader Luncheon for Investors Focused on Angiosarcoma and Prostate Cancer on December 1 in New York City
  17. TRACON Pharmaceuticals Announces Proposed Public Offering of Common Stock
  18. TRACON Pharmaceuticals Announces Proposed Public Offering of Common Stock
  19. TRACON PHARMACEUTICALS, INC. Financials
  20. TRACON PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits

SEC Filings

  1. 8-K - Current report 17515665
  2. 8-K - Current report 17502174
  3. 8-K - Current report 162062499
  4. 8-K - Current report 162049641
  5. SC 13D/A [Amend] - General statement of acquisition of beneficial ownership 162040723
  6. 8-K - Current report 162016655
  7. 424B5 - Prospectus [Rule 424(b)(5)] 162016593
  8. 424B5 - Prospectus [Rule 424(b)(5)] 162013231
  9. 8-K - Current report 161994858
  10. 10-Q - Quarterly report [Sections 13 or 15(d)] 161982354